Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Asylia Therapeutics is raising $16,193,628.00 in new funding. Sources indicate as part of senior management President, Elan Ezickson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Asylia Therapeutics

Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer, autoimmune and infectious diseases. Founded in 2019 and based in Houston, Texas, the company is led by a seasoned team of entrepreneurs, scientific leaders in immunity, oncology and clinical trials, and biotech executives with experience in antibody drug and business development.

To learn more about Asylia Therapeutics, visit http://asyliatx.com/

Contact:
Elan Ezickson, President
617-921-9645
https://www.linkedin.com/in/elan-ezickson-5a4a091/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved